In addition to an overview of the blow/fill/seal (BFS) technology, Mr. Weichbrodt will discuss current applications and the flexibility of BFS over other aseptic filling methods. He will also present a case study demonstrating the microbial performance of BFS and, when compared to more traditional methods of aseptic filling, suggest advantages to the process that may ensure the highest quality standards, reduce regulatory risks and enhance product performance and safety.
As well as a broad range of development and manufacturing services, Catalent provides customizable, specialty fill-finish solutions including BFS technology. Because of its unrivalled industry expertise, the company is able to provide customized manufacturing options for the most complex treatments, including emulsions and suspensions, ensuring a reliable global supply with an uncompromising commitment to quality.
Norman Weichbrodt has been with Catalent for more than ten years, and has 30+ years' experience within the pharmaceutical industry. He is experienced in all phases of aseptic processing including formulation, sterile filling, lyophilization and secondary packaging. During his career he has served in a variety of senior manufacturing and technical roles. He currently works in the New Product Development Group at Catalent's BFS facility in Woodstock, Illinois, managing technical transfers and product development for strategic customers.
Pharma Congress 2012 takes place in the SwissĂ´telCongress Center in Dusseldorf, Germany, on 24th and 25th April 2012 and incorporates five international conferences. Mr. Weichbrodt's presentation will be made during âECA Conference on Current Aseptic Technologiesâ at 16:45 on the first day of the conference. For more information on Pharma Congress 2012, visit here.
Companies in this article
